Restylane® Refyne & Restylane® Defyne Are Now Approved!
Next-Generation Flexible Hyaluronic Acid Dermal Fillers Provide Natural-Looking Results Through XpresHAn Technology
Restylane Chevy Chase
Galderma, a global leader focused on medical solutions in skin health, recently announced that it has received U.S. Food and Drug Administration (FDA) approval for two new products for the treatment of nasolabial folds (NLF) or “laugh lines.”
Unlike other fillers that are already on the market, Restylane Defyne and Restylane Refyne incorporate a special XpresHAn technology, deeming these products as next-generation hyaluronic acid fillers.
Restylane Refyne Chevy Chase / Restylane Defyne Chevy Chase
“With over 30 million treatments worldwide and counting, the Restylane line of hyaluronic acid fillers is incredible for accentuated lips and adding lift and volume to the cheeks,” said Dr. Tina West of The West Institute in Chevy Chase, MD.
“Now we are thrilled to be one of the first practices in the area to offer even more natural results with the new addition of Restylane Refyne and Restylane Defyne,” said Dr. West.
The XpresHAn technology allows for the product to move within the face as facial expressions are made to prevent a fake, injected or unnatural look.
“Even with current approved options, many of my patients are still looking for different solutions to treat their laugh lines,” said Boca Raton-based oculoplastic surgeon and Restylane® Refyne clinical investigator, Steven Fagien, MD.
“These new products are flexible and are designed to meet different patient needs. I am excited to offer these next-generation hyaluronic acid (HA) dermal fillers in my practice.”
“Restylane® Refyne and Restylane® Defyne are the latest FDA-approved advancements in HA dermal fillers and align with Galderma’s mission to help individuals achieve natural-looking results through treatments with a long-standing history of proven safety and efficacy,” said Kelly Huang, PhD – VP & General Manager of the U.S. Aesthetic and Corrective business of Galderma.
“We saw an opportunity to address a common concern for patients who have not yet tried a dermal filler by designing gels that provide natural-looking results. With these new brands, the Restylane® family of products now represents the broadest offering of HA dermal fillers in the U.S.”
The FDA approval was based on two pivotal, double-blinded, randomized, active-controlled Phase 3 studies investigating Restylane® Refyne and Restylane® Defyne (involving 171 and 162 subjects, respectively) to evaluate their safety and effectiveness.
In both studies, Restylane® Refyne and Restylane® Defyne met the studies’ endpoints, with both products showing a clinically meaningful improvement in wrinkle severity for up to 12 months in the majority of patients.
Study investigators used the Wrinkle Severity Rating Scale (WSRS), a validated 5-point measure of the size and depth of the wrinkles, with grade 1 defined as absence of wrinkles and grade 5 as extremely deep and long wrinkles.
Investigators reported that 79 percent of Restylane® Refyne subjects and 77 percent of Restylane® Defyne subjects had at least a 1-grade improvement on the WSRS after six weeks.
Subjects also performed self-assessments (SSA) of wrinkle severity, with most subjects reporting at least a one-grade improvement in SSA scores with Restylane® Refyne and with Restylane® Defyne after six weeks.
“Many of my patients are interested to learn about the latest products that can help them achieve natural-looking results, but are oftentimes unsure about starting dermal fillers,” said San Diego-based board-certified dermatologist Mitch Goldman, MD.
“The introduction of these next-generation HA dermal fillers with XpresHAn Technology has the potential to change my patients’ views on fillers. Restylane® Refyne and Restylane® Defyne provide options for patients who want to make sure they can achieve results that provide options for patients who want to make sure they can achieve natural-looking results which is a key need my patients express every day.”
After initial treatment, injection site responses (redness, swelling, bruising, lump/bump formation, pain/tenderness) were predominantly mild or moderate in intensity, temporary (typically with a duration of one to two weeks), and similar for the Restylane® products.